BellBrook Labs Recap of SLAS 2019 in Washington DC.
Tuesday, 29 January 2019
- Published in Company, HTS Assays
No Comments
NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer
Tuesday, 22 May 2018
- Published in Company, Emerging Targets, News
Discovery on Target 2017
Tuesday, 05 September 2017
Here is what you may have missed… Exhibition Learn about our new AptaFluor SAH Methyltransferase Assay Discuss which HTS assays might be a fit for your research Discover how BellBrook Labs’ services can help accelerate your drug discovery program Presentations/Talks Targeting the cGAS-STING Pathway Using a Homogenous, HTS Compatible Transcreener® cGAS Assay Thursday, September
New Publication: HTS Method for Measuring Drug Residence Time
Tuesday, 25 April 2017
View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
- Published in Company, HTS Assays, News
Detecting Rho-GEF Activity Using the Transcreener® GDP Assay
Friday, 24 March 2017
Rho GTPases act as molecular switches to regulate the cytoskeletal dynamics underlying cell motility. Rho GEFs (guanine nucleotide exchange factors) positively regulate Rho GTPases by accelerating GDP dissociation and allowing formation of the active GTPase-GTP complex. Active Rho GTPases typically stimulate cell growth and migration, sometimes triggering tumorigenesis or invasion. Selectively disrupting GEF action using
- Published in Company, HTS Assays, Products
BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services
Wednesday, 22 February 2017
Madison, WI, February 2017 – In response to an increasing demand for characterization and prioritization of compounds downstream of HTS or virtual screening, BellBrook Labs is expanding its Drug Discovery Services to include Lead Discovery in addition to Assay Development. BellBrook will use its proprietary Transcreener® HTS assay platform to accelerate clients’ hit-to-lead and SAR
SLAS Conference 2017 Recap
Tuesday, 14 February 2017
SLAS Conference 2017 Recap Here is what you may have missed… Discussions at the Exhibit Included The expansion of BellBrooks’s Drug Discovery Services What’s new in the field of HTS sssays How Transcreener® Assays are accelerating drug discovery Current challenges to the field of drug discovery and potential solutions moving forward Posters Presented at the Conference
What’s New at BellBrook Labs? Find Out at SLAS 2017.
Friday, 20 January 2017
SLAS 2017 Meeting February 4th-8th Walter E. Washington Convention Center Washington, DC Exhibition Visit Booth #245 to: Learn about the expansion of BellBrooks’s Drug Discovery Services Discuss which HTS assays might be a fit for your research Discover how Transcreener® Assays are accelerating drug discovery Poster Presentations A Homogenous, Universal Enzymatic Assay for Histone Methyltransferases Based
BellBrook Labs Awarded NIH Grant to Validate New Target for Liver Fibrosis Using Transcreener GTPase Assay Platform
Wednesday, 09 November 2016
BellBrook Labs was awarded a Phase I Small Business Innovative Research (SBIR) grant of $353,000 from the National Institute on Alcohol Abuse and Alcoholism for pharmacological validation of GIV, a nonreceptor guanine nucleotide exchange factor (GEF), as a therapeutic target for liver fibrosis. BellBrook will use proprietary high throughput GTPase assay methods to identify small
- 1
- 2
